Rufinamide: Crystal structure elucidation and solid state characterization

dc.contributor.author Salunke, Nita
dc.contributor.author Thipparaboina, Rajesh
dc.contributor.author Chavan, Rahul B.
dc.contributor.author Lodagekar, Anurag
dc.contributor.author Mittapalli, Sudhir
dc.contributor.author Nangia, Ashwini
dc.contributor.author Shastri, Nalini R.
dc.date.accessioned 2022-03-27T09:22:48Z
dc.date.available 2022-03-27T09:22:48Z
dc.date.issued 2018-02-05
dc.description.abstract Rufinamide (R) is a triazole derivative approved for the management of partial seizures and seizures associated with Lennox-Gastaut Syndrome, in November 2007. Crystal structure, solid state characterization, drug-excipient compatibility and solubility play a pivotal role in formulation development. This work deals with the crystal structure elucidation of R by single crystal X-ray diffraction and solid state characterization by thermal, spectroscopic and crystallographic techniques. Drug- excipient compatibility was assessed by differential scanning calorimetry (DSC). New RP-HPLC method for quantification of R was developed with improved retention time. Solubility and dissolution of drug in different media was determined. Additionally, the flow behavior of the drug was evaluated by measuring Carr's index and Hausner's ratio, while the compressibility behavior was studied using Well's protocol. R crystallized from dimethylformamide (R-DMF) was utilized for single crystal analysis. The drug crystallized in triclinic crystal system with P-1 space group. Asymmetric unit cell consists of two molecules of R held by intermolecular hydrogen bond (connected by N[sbnd]H⋯O, which forms the catemeric chain). Analytical outcomes from DSC, thermogravimetric analysis (TGA) and powder X-ray diffraction (PXRD) revealed that the drug was present in pure crystalline form and was devoid of any polymorphic or pseudopolymorphic impurities. Influence of pH on the solubility and dissolution of R-DMF was found to be insignificant. The drug exhibited poor aqueous solubility, which was improved nearly 4.6 fold with the addition of 2% sodium lauryl sulphate (SLS). The drug exhibits poor flow and elastic compression nature. Excipients such as poly ethylene glycol (PEG) 8000, SLS, lactose monohydrate, starch and Hydroxypropyl methylcellulose (HPMC) E15 were incompatible with R-DMF as identified by thermal analysis. It is envisaged that these information regarding solid state properties of R-DMF would aid in identifying a logical path for formulation development.
dc.identifier.citation Journal of Pharmaceutical and Biomedical Analysis. v.149
dc.identifier.issn 07317085
dc.identifier.uri 10.1016/j.jpba.2017.11.003
dc.identifier.uri https://www.sciencedirect.com/science/article/abs/pii/S0731708517313742
dc.identifier.uri https://dspace.uohyd.ac.in/handle/1/12829
dc.subject Compressibility
dc.subject Dissolution media
dc.subject DSC
dc.subject HPLC method
dc.subject Solubility
dc.title Rufinamide: Crystal structure elucidation and solid state characterization
dc.type Journal. Article
dspace.entity.type
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: